Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Receivables: 2020-2025

Historic Receivables for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $2.1 million.

  • Caribou Biosciences' Receivables rose 10.87% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year decrease of 8.61%. This contributed to the annual value of $2.1 million for FY2024, which is 14.01% down from last year.
  • As of Q3 2025, Caribou Biosciences' Receivables stood at $2.1 million, which was up 2.12% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Receivables registered a high of $7.6 million during Q2 2021, and its lowest value of $1.9 million during Q3 2024.
  • In the last 3 years, Caribou Biosciences' Receivables had a median value of $2.1 million in 2024 and averaged $2.4 million.
  • As far as peak fluctuations go, Caribou Biosciences' Receivables surged by 73.17% in 2021, and later tumbled by 63.10% in 2022.
  • Caribou Biosciences' Receivables (Quarterly) stood at $6.6 million in 2021, then slumped by 63.10% to $2.4 million in 2022, then dropped by 0.61% to $2.4 million in 2023, then dropped by 14.01% to $2.1 million in 2024, then climbed by 10.87% to $2.1 million in 2025.
  • Its Receivables was $2.1 million in Q3 2025, compared to $2.0 million in Q2 2025 and $1.9 million in Q1 2025.